Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASNB
EKIMAS
$0.61
$0.56
$0.55
$1.75
$3.54M0.373,162 shsN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
$0.00
$0.00
$0.01
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$4.37
-4.4%
$3.80
$2.70
$11.68
$8.70M2.2643,699 shs13,337 shs
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
$0.58
$0.22
$2.40
$997K0.658.25 million shs1.89 million shs
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
$0.04
-7.1%
$0.09
$0.02
$1.82
$801K1.4721.67 million shs18.22 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASNB
EKIMAS
0.00%0.00%0.00%+12.96%-22.78%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
0.00%0.00%0.00%0.00%-98.00%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
+5.54%+28.01%+10.12%+52.33%-60.87%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
0.00%0.00%0.00%-50.67%-75.70%
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
-9.09%+73.52%-58.92%-87.84%-97.90%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ASNB
EKIMAS
N/AN/AN/AN/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASNB
EKIMAS
N/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
2.00
HoldN/AN/A

Current Analyst Ratings

Latest NURO, NVIV, ASNB, SINT, and MDIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/5/2024
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASNB
EKIMAS
N/AN/AN/AN/A$0.03 per shareN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
$5.90M1.47N/AN/A$13.18 per share0.33
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/A$6.48 per shareN/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
$2.63M0.30N/AN/A$1.65 per share0.02

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASNB
EKIMAS
-$290KN/A0.00N/AN/A-7,902.31%-5,274.01%N/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
-$6.53M-$6.23N/AN/A-110.64%-31.31%-29.32%5/1/2024 (Estimated)
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
-$8.26M-$3.42N/AN/A-314.39%-67.12%-45.49%5/20/2024 (Estimated)

Latest NURO, NVIV, ASNB, SINT, and MDIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2024Q4 2023
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
N/A-$0.09-$0.09-$0.09N/A$0.90 million
2/22/2024Q4 2023
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A-$1.43-$1.43-$1.43N/A$1.32 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ASNB
EKIMAS
N/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASNB
EKIMAS
N/A
0.12
0.12
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
N/A
16.80
15.55
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/A
14.30
14.30
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
N/A
1.90
1.60

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ASNB
EKIMAS
N/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/A
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
19.40%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
13.78%
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
18.38%

Insider Ownership

CompanyInsider Ownership
ASNB
EKIMAS
7.80%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
85.40%
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
4.40%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
2.45%
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
0.79%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ASNB
EKIMAS
115.80 million5.35 millionNot Optionable
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
69N/AN/ANot Optionable
NeuroMetrix, Inc. stock logo
NURO
NeuroMetrix
261.99 million1.90 millionNot Optionable
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
63.11 million3.03 millionNot Optionable
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
4122.68 million22.50 millionNot Optionable

NURO, NVIV, ASNB, SINT, and MDIT Headlines

SourceHeadline
Why SINTX Technologies Stock Is Getting HammeredWhy SINTX Technologies Stock Is Getting Hammered
msn.com - April 3 at 2:48 PM
SINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common StockSINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common Stock
globenewswire.com - April 3 at 9:00 AM
Why SINTX Technologies Stock Hit A New All-Time Low TodayWhy SINTX Technologies Stock Hit A New All-Time Low Today
msn.com - April 1 at 3:51 PM
DDC Appoints Vice President to Drive Operational ExcellenceDDC Appoints Vice President to Drive Operational Excellence
itnewsonline.com - March 30 at 6:23 PM
SINTX Technologies Announces Proposed Public Offering of Common StockSINTX Technologies Announces Proposed Public Offering of Common Stock
globenewswire.com - March 29 at 4:00 PM
SINT Stock Earnings: SINTX Technologies Beats EPS, Beats Revenue for Q4 2023SINT Stock Earnings: SINTX Technologies Beats EPS, Beats Revenue for Q4 2023
investorplace.com - March 28 at 7:02 AM
Sintx Technologies Prices Public Offering Of $1.3 Mln Of SharesSintx Technologies Prices Public Offering Of $1.3 Mln Of Shares
markets.businessinsider.com - March 25 at 1:22 PM
Why SINTX Technologies Stock Is Down 50%Why SINTX Technologies Stock Is Down 50%
msn.com - March 25 at 1:22 PM
Why Is Sintx Technologies (SINT) Stock Down 31% Today?Why Is Sintx Technologies (SINT) Stock Down 31% Today?
investorplace.com - March 25 at 9:05 AM
SINTX Technologies Announces Pricing of $1.3 Million Public Offering of Common StockSINTX Technologies Announces Pricing of $1.3 Million Public Offering of Common Stock
globenewswire.com - March 25 at 9:00 AM
US Stocks Edge Lower; FedEx Posts Upbeat EarningsUS Stocks Edge Lower; FedEx Posts Upbeat Earnings
msn.com - March 23 at 3:15 AM
Why SINTX Technologies Is Trading Higher TodayWhy SINTX Technologies Is Trading Higher Today
aol.com - March 22 at 10:14 PM
Gold Moves Lower; Lululemon Shares PlummetGold Moves Lower; Lululemon Shares Plummet
msn.com - March 22 at 5:14 PM
Dow Dips 200 Points; Nike Shares Fall After Q3 ResultsDow Dips 200 Points; Nike Shares Fall After Q3 Results
markets.businessinsider.com - March 22 at 5:14 PM
SINTX Technologies Announces Intend To Offer And Sell Shares Of Common Stock; Stock Down 34%SINTX Technologies Announces Intend To Offer And Sell Shares Of Common Stock; Stock Down 34%
markets.businessinsider.com - March 22 at 5:14 PM
Why SINTX Technologies Stock Is NosedivingWhy SINTX Technologies Stock Is Nosediving
msn.com - March 22 at 5:14 PM
SINTX Technologies Announces Proposed Public Offering of Common StockSINTX Technologies Announces Proposed Public Offering of Common Stock
globenewswire.com - March 22 at 8:30 AM
Sintx Technologies (SINT) Price Target Increased by 42.86% to 10.20Sintx Technologies (SINT) Price Target Increased by 42.86% to 10.20
msn.com - February 24 at 2:14 PM
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
benzinga.com - February 23 at 7:50 AM
SINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKETSINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKET
finance.yahoo.com - February 21 at 3:58 PM
SINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKETSINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKET
globenewswire.com - February 21 at 9:00 AM
SINTX Technologies: Other EventsSINTX Technologies: Other Events
cbonds.com - February 16 at 10:37 AM
SINTX Technologies subsidiary enters R&D agreement with the U.S. Army DEVCOM ARL for ceramic additive manufacturingSINTX Technologies subsidiary enters R&D agreement with the U.S. Army DEVCOM ARL for ceramic additive manufacturing
tctmagazine.com - February 7 at 10:57 AM
Sintx Technologies just downgraded at Maxim, heres whySintx Technologies just downgraded at Maxim, here's why
realmoney.thestreet.com - February 5 at 5:59 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

EKIMAS

OTCMKTS:ASNB
EKIMAS Corp. engages in the development of polymer materials, which provide characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. The firm's products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Las Vegas, NV.
Medite Cancer Diagnostics logo

Medite Cancer Diagnostics

OTCMKTS:MDIT
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
NeuroMetrix logo

NeuroMetrix

NASDAQ:NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
InVivo Therapeutics logo

InVivo Therapeutics

NASDAQ:NVIV
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.
Sintx Technologies logo

Sintx Technologies

NASDAQ:SINT
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.